MGMT and central nervous system cancer: In contrast, MGMT promoter methylation has been shown to be a strong biomarker of prognosis and a predictor of response to chemotherapy, reinforcing the idea that this biomarker should be include in glioma classification, resulting in a new molecular subgroup within the GBM IDH-wildtype.